Canadian Journal of Gastroenterology and Hepatology / 2019 / Article / Tab 4 / Research Article
As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib Table 4 Univariate and multivariate analyses of different type of adverse events for overall survival.
Adverse events Patients (%) Univatiate analyses Multivariate analyses Unadjusted HR (95% CI) ValueAdjusted HR (95% CI) Value≥1 grade of adverse events Any 218 (92.8) 0.45 (0.26–0.76) 0.003 0.47 (0.27–0.82) 0.008 HFSR 182 (77.5) 0.59 (0.43–0.81) 0.001 0.70 (0.50–0.98) 0.038 Alopecia 156 (66.4) 0.79 (0.59–1.06) 0.122 0.75 (0.55–1.03) 0.076 Rash 124 (52.8) 0.99 (0.75–1.31) 0.944 0.81 (0.61–1.08) 0.154 Diarrhea 100 (42.6) 0.85 (0.64–1.22) 0.478 0.72 (0.53–0.97) 0.029 Fatigue 102 (43.4) 1.34 (1.01–1.77) 0.039 0.95 (0.70–1.28) 0.725 Voice change 46 (19.6) 1.08 (0.76–1.52) 0.679 0.69 (0.46–1.02) 0.062 Dental ulcer 26 (11.1) 0.79 (0.50–1.23) 0.295 0.74 (0.47–1.17) 0.198 Hypertension 29 (12.3) 0.84 (0.56–1.28) 0.425 0.92 (0.60–1.41) 0.704 ≥2 grade of adverse events Any 174 (74.0) 0.51 (0.38–0.70) <0.001 0.42 (0.30–0.59) <0.001 HFSR 125 (53.2) 0.43 (0.33–0.57) <0.001 0.43 (0.32–0.58) <0.001 Rash 61 (26.0) 0.89 (0.66–1.22) 0.478 0.75 (0.55–1.04) 0.081 Diarrhea 52 (22.1) 1.02 (0.74–1.41) 0.891 1.07 (0.76–1.50) 0.697 ≥3 grade of adverse events Any 59 (25.1) 0.73 (0.53–1.01) 0.060 0.65 (0.46–0.91) 0.013 HFSR 45 (19.1) 0.70 (0.48–1.00) 0.051 0.68 (0.47–1.00) 0.051
Abbreviations: HR, hazard ratio; CI, confidence interval; HFSR, hand-foot-skin reaction.